Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Coronavirus Economic Update: Business Casual

With the number of coronavirus cases worldwide approaching 80,000 (most of them in China) with 35 cases already reported in the U.S., and a death toll that now tops 2,600, both American and international companies are apprehensive over the likely economic impacts, warning that reduced flows into and out of the world’s second-largest economy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

With the number of coronavirus cases worldwide approaching 80,000 (most of them in China) with 35 cases already reported in the U.S., and a death toll that now tops 2,600, both American and international companies are apprehensive over the likely economic impacts, warning that reduced flows into and out of the world’s second-largest economy will have a tangible effect on business and product availability throughout the world.

Today, there remains huge uncertainty about how widely the virus will spread and how much damage it will do. But in America, where the S&P 500 hit a new high last Wednesday, this week, after reports of people infected with the virus in the major economies of South Korea and Italy, the S&P dropped more than 7 percent. Further, on Tuesday, yields on 10-year United States Treasury bonds fell to their lowest levels on record, suggesting investors expect significant economic damage and accompanying Federal Reserve interest-rate cuts.

Taking a growing toll on the U.S. economy, Mark Zandi, Chief Economist of Moody’s Analytics, estimates the outbreak will reduce growth during the first three months of 2020 by six-tenths of a percentage point to 1.3%, chiefly through reduced travel and tourism and manufacturers who will likely export less to Asia and Europe as demand there slackens.

In this Business Casual segment, Daniel Litwin and Taylor Bagley take on the coronavirus issue, and examine the current economic impacts as well as the potential consequences should the virus spread further and make significant landfall here on our country’s shores.

“What we really need to work on now is getting accurate information, the right information about how many people have been affected by this, how we can actually contain this,” Bagley stated.

“We need to prepare for the reality that if it does hit the United States in a more aggressive way, that we’re really going to be testing our mobile workforce honestly. People are going to be working from home, schools are going to be canceled—what does that look like,” Litwin said. “So, day-to-day could change a lot and that would impact our economy substantially.”

For more Business Casual, listen live on MarketScale Radio on Wednesdays and Fridays at 9 AM CT, and follow us on Twitter at @BizCasualRadio.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512